NO985297L - FremgangsmÕte for fremstilling av et rekombinant polypeptid omfattende tils - Google Patents

FremgangsmÕte for fremstilling av et rekombinant polypeptid omfattende tils

Info

Publication number
NO985297L
NO985297L NO985297A NO985297A NO985297L NO 985297 L NO985297 L NO 985297L NO 985297 A NO985297 A NO 985297A NO 985297 A NO985297 A NO 985297A NO 985297 L NO985297 L NO 985297L
Authority
NO
Norway
Prior art keywords
cell culture
culture medium
chymotrypsins
hemophilia
inhibitor
Prior art date
Application number
NO985297A
Other languages
English (en)
Other versions
NO985297D0 (no
NO325358B1 (no
Inventor
Lars Adamson
Erik Walum
Johan Dixelius
Kristina Lima Lie
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9601855A external-priority patent/SE9601855D0/xx
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of NO985297D0 publication Critical patent/NO985297D0/no
Publication of NO985297L publication Critical patent/NO985297L/no
Publication of NO325358B1 publication Critical patent/NO325358B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
NO19985297A 1996-05-14 1998-11-13 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant human blodkoaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet. NO325358B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9601855A SE9601855D0 (sv) 1996-05-14 1996-05-14 Process for producing a protein
US1887496P 1996-05-29 1996-05-29
PCT/SE1997/000783 WO1997043436A1 (en) 1996-05-14 1997-05-13 A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium

Publications (3)

Publication Number Publication Date
NO985297D0 NO985297D0 (no) 1998-11-13
NO985297L true NO985297L (no) 1999-01-14
NO325358B1 NO325358B1 (no) 2008-04-07

Family

ID=26662616

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19985297A NO325358B1 (no) 1996-05-14 1998-11-13 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant human blodkoaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet.
NO20065027A NO325633B1 (no) 1996-05-14 2006-11-02 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20065027A NO325633B1 (no) 1996-05-14 2006-11-02 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet

Country Status (13)

Country Link
US (1) US5851800A (no)
EP (1) EP0934424B1 (no)
JP (2) JP2000509994A (no)
AT (2) ATE321141T1 (no)
AU (1) AU716245B2 (no)
CA (1) CA2253287C (no)
DE (2) DE69736391T2 (no)
DK (1) DK0934424T3 (no)
ES (2) ES2260524T3 (no)
NO (2) NO325358B1 (no)
NZ (1) NZ332751A (no)
PT (2) PT1318198E (no)
WO (1) WO1997043436A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
DK2193809T3 (en) 1999-02-22 2015-05-26 Univ Connecticut The albumin-free Factor VIII formulation
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
EP1200561B1 (de) * 1999-08-05 2006-06-14 Baxter Aktiengesellschaft Rekombinanter stabiler zellklon, seine herstellung und verwendung
WO2001052891A1 (fr) * 2000-01-20 2001-07-26 Nippon Organon K. K. Inhibiteurs d'invasion plasmodiale dans des erythrocytes
AU2003249990B2 (en) * 2002-07-09 2007-06-28 Takeda Pharmaceutical Company Limited Animal protein free media for cultivation of cells
BR0316882A (pt) * 2002-12-23 2005-10-25 Bristol Myers Squibb Co Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
US20040265964A1 (en) * 2003-04-25 2004-12-30 Martin Allen Inducers of recombinant protein expression
US7255288B2 (en) * 2004-03-08 2007-08-14 Wan Shan Chan Aroma therapy for fountain
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
PT1974014T (pt) 2006-01-04 2017-05-26 Baxalta Inc Meios de cultura celulares livres de oligopeptídeos
EP2126106B1 (en) * 2007-02-23 2017-09-06 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
WO2008135498A2 (en) * 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2012045769A1 (en) 2010-10-05 2012-04-12 Novo Nordisk Health Care Ag Process for protein production
WO2014062535A1 (en) 2012-10-15 2014-04-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
RU2741345C2 (ru) 2015-10-28 2021-01-25 Юхан Корпорейшн Белки с двойной функцией и содержащая их фармацевтическая композиция
SI3368554T1 (sl) 2015-10-28 2020-10-30 Yuhan Corporation Dolgo-delujoči FGF21 fuzijski proteini in farmacevtski sestavek, ki obsega le-te
AU2017358289A1 (en) 2016-11-10 2019-06-20 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
JP7191850B2 (ja) 2017-04-21 2022-12-19 ユーハン・コーポレイション デュアル機能タンパク質およびその誘導体を生産するための方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149787A (en) * 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
US5279939A (en) * 1986-08-18 1994-01-18 Smithkline Beecham Corporation Protein protease inhibitors from streptomyces
US4891356A (en) * 1987-07-15 1990-01-02 Brigham & Women's Hospital Proteinase inhibitors for treatment of gastrointestinal ulcer disease
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
JP2769170B2 (ja) * 1987-12-08 1998-06-25 ザイモジェネティクス，インコーポレイティド 真核細肪中での同時発現
WO1990002175A1 (en) * 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
DK457788D0 (da) * 1988-08-16 1988-08-16 Nordisk Gentofte Fremgangsmaade til fremstilling af et oensket polypeptid
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
ES2180529T3 (es) * 1990-02-26 2003-02-16 Univ Leland Stanford Junior Identificacion y expresion de secuencias de adn de un receptor de esteroides de insectos.
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
US5661034A (en) * 1991-07-18 1997-08-26 Fuji Yakuhin Kogyo Kabushiki Kaisha Serum-free medium for tissue culture containing tissue inhibitor of metalloproteinases and method for growing cells using the medium
WO1993006217A1 (en) * 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
US5278289A (en) * 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
WO1995005477A1 (en) * 1993-08-12 1995-02-23 University Of Maryland Thermostable alkaline metalloprotease produced by a hyphomonas, and preparation thereof
US5631159A (en) * 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5543396A (en) * 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives

Also Published As

Publication number Publication date
JP4896999B2 (ja) 2012-03-14
NO20065027L (no) 1999-01-14
DK0934424T3 (da) 2006-11-20
CA2253287A1 (en) 1997-11-20
AU2919797A (en) 1997-12-05
DE69735510D1 (de) 2006-05-11
NO985297D0 (no) 1998-11-13
DE69736391D1 (de) 2006-09-07
ES2270460T3 (es) 2007-04-01
NZ332751A (en) 2000-06-23
WO1997043436A1 (en) 1997-11-20
PT1318198E (pt) 2006-08-31
US5851800A (en) 1998-12-22
DE69735510T2 (de) 2006-08-24
ATE334223T1 (de) 2006-08-15
ES2260524T3 (es) 2006-11-01
JP2009148271A (ja) 2009-07-09
NO325633B1 (no) 2008-06-30
ATE321141T1 (de) 2006-04-15
EP0934424B1 (en) 2006-07-26
CA2253287C (en) 2008-02-19
PT934424E (pt) 2006-12-29
JP2000509994A (ja) 2000-08-08
EP0934424A1 (en) 1999-08-11
NO325358B1 (no) 2008-04-07
DE69736391T2 (de) 2007-08-16
AU716245B2 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
NO985297L (no) FremgangsmÕte for fremstilling av et rekombinant polypeptid omfattende tils
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
ES2093025T3 (es) Produccion del factor de crecimiento de celulas endoteliales y adn de codificacion del mismo.
AU576365B2 (en) Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas
ATE92107T1 (de) N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
KR960703433A (ko) 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
IL177228A0 (en) Use of a vector for the manufacture of a medicament for treating gaucher disease
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
ATE234108T1 (de) Therapeutikum zur unterdrückung von schnarchgeräuschen
DE68928718D1 (de) Human-Nervenwachstumsfaktor
DE69530303D1 (de) Neue verwendung von prostaglandinen
DE68926679T2 (de) Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
DK0832186T3 (da) Erstatningsterapi til dental caries
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
HUP9901188A2 (hu) Új, meghatározott enzimkeverékek sejtkinyeréshez és sebkezeléshez
NO177859C (no) Fremgangsmåte til produksjon av angiogen faktor
JPH06509057A (ja) 促進された創傷治癒
PT883406E (pt) Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente
FI102844B1 (fi) Menetelmä valmistaa parannettu terapeuttisesti aktiivinen kudosplasminogeenin aktivaattori
SE9300509D0 (sv) Peg treatment
JPS6427472A (en) Production of human tissue plasminogen activator and cell strain using therein
MX9800686A (es) Nueva proteina hmw humana mp52s.
UA7955A (uk) Спосіб лікування туберкульозу легенів

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees